Evaluation of ART Scores for Repeated Transarterial Chemoembolization in Japanese Patients with Hepatocellular Carcinoma

被引:24
作者
Arizumi, Tadaaki [1 ]
Ueshima, Kazuomi [1 ]
Iwanishi, Mina [1 ]
Minami, Tomohiro [1 ]
Chishina, Hirokazu [1 ]
Kono, Masashi [1 ]
Takita, Masahiro [1 ]
Kitai, Satoshi [1 ]
Inoue, Tatsuo [1 ]
Yada, Norihisa [1 ]
Hagiwara, Satoru [1 ]
Ida, Hiroshi [1 ]
Minami, Yasunori [1 ]
Sakural, Toshiharu [1 ]
Nishida, Naoshi [1 ]
Kitano, Masayuki [1 ]
Kudo, Masatoshi [1 ]
机构
[1] Kinki Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka 5898511, Japan
关键词
Transarterial chemoembolization; Hepatocellular carcinoma; ART score; Overall survival; CLINICAL-PRACTICE GUIDELINES; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; UNITED-STATES; LIVER-CANCER; MANAGEMENT; INTERMEDIATE; REFRACTORINESS; SURVEILLANCE; RETREATMENT; SORAFENIB;
D O I
10.1159/000440625
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Transarterial chemoembolization (TACE) is recommended as a first-line therapy for hepatocellular carcinoma (HCC) patients ineligible for curative therapy and without portal invasion. The Assessment for Retreatment with TACE (ART) scoring system was recently proposed for identifying patients who would not show sufficient survival benefit from repeated TACE. We reevaluated the performance of ART in HCC patients treated in Japan, where selective TACE is commonly used. Methods: Between 2000 and 2013, 988 patients with HCC underwent TACE at Kinki University Hospital, and 627 received >= 2 sessions of TACE. Seventy-six patients who underwent >= 2 TACE sessions within 90 days were investigated for their performance of the ART score in the context of overall survival (OS). Results: Only 12% (76/627) of patients underwent >= 2 TACE sessions within 90 days. Of those, 52 patients showed a low ART score (0-1.5), and 24 had a high ARTscore (>= 2.5); the median OS was 20.2 and 37.6 months, respectively (p = 0.8207). Conclusion:The ART scoring system did not demonstrate a sufficiently predictive impact on OS among the patients who underwent 2 TACE sessions within 90 days. Application of the ART score should be carefully considered because differences in TACE procedures and post-TACE treatment can affect the results while evaluating OS. (C) 2015 S. Karger AG, Basel
引用
收藏
页码:4 / 10
页数:7
相关论文
共 34 条
  • [1] Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005
    Altekruse, Sean F.
    McGlynn, Katherine A.
    Reichman, Marsha E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) : 1485 - 1491
  • [2] Validation of the Criteria of Transcatheter Arterial Chemoembolization Failure or Refractoriness in Patients with Advanced Hepatocellular Carcinoma Proposed by the LCSGJ
    Arizumi, Tadaaki
    Ueshima, Kazuomi
    Chishina, Hirokazu
    Kono, Masashi
    Takita, Masahiro
    Kitai, Satoshi
    Inoue, Tatsuo
    Yada, Norihisa
    Hagiwara, Satoru
    Minami, Yasunori
    Sakurai, Toshiharu
    Nishida, Naoshi
    Kudo, Masatoshi
    [J]. ONCOLOGY, 2014, 87 : 32 - 36
  • [3] Chemoembolization for hepatocellular carcinoma
    Bruix, J
    Sala, M
    Llovet, JM
    [J]. GASTROENTEROLOGY, 2004, 127 (05) : S179 - S188
  • [4] Management of Hepatocellular Carcinoma: An Update
    Bruix, Jordi
    Sherman, Morris
    [J]. HEPATOLOGY, 2011, 53 (03) : 1020 - 1022
  • [5] Treatment Algorithm for Intermediate and Advanced Stage Hepatocellular Carcinoma: Korea
    Choi, Jong Young
    [J]. ONCOLOGY, 2011, 81 : 141 - 147
  • [6] CURRENT CONCEPTS Hepatocellular Carcinoma
    El-Serag, Hashem B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (12) : 1118 - 1127
  • [7] The Size of the Problem: Clinical Algorithms
    Forner, Alejandro
    Bruix, Jordi
    [J]. DIGESTIVE DISEASES, 2013, 31 (01) : 95 - 103
  • [8] Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia
    Han, Kwang-Hyub
    Kudo, Masatochi
    Ye, Sheng-Long
    Choi, Jong Young
    Poon, Roonni Tung-Ping
    Seong, Jinsil
    Park, Joong-Won
    Ichida, Takafumi
    Chung, Jin Wook
    Chow, Pierce
    Cheng, Ann-Lii
    [J]. ONCOLOGY, 2011, 81 : 158 - 164
  • [9] Epidemiology and Surveillance of Hepatocellular Carcinoma
    Kim, Do Young
    Han, Kwang-Hyub
    [J]. LIVER CANCER, 2012, 1 (01) : 2 - 14
  • [10] Locoregional Therapy for Hepatocellular Carcinoma
    Kudo, M.
    [J]. LIVER CANCER, 2015, 4 (03) : 163 - 164